Physician profile
Alan D Olmstead
NPI 1306936794
$404,549.66
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $32K · 2021: $39K · 2022: $73K · 2023: $51K · 2024: $55K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $40K · Food and Beverage: $3,893 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,000.00 |
| Travel and Lodging | $40,265.79 |
| Food and Beverage | $3,892.59 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331,714.94 | 2019-2025 | |
| Amgen INC. | $41,457.27 | 2020-2023 | Otezla |
| Celgene Corporation | $15,634.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14,430.92 | 2019-2023 | |
| Ucb, INC. | $509.78 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $128.70 | 2021-2023 | Ilumya |
| Pfizer INC. | $109.99 | 2020-2024 | |
| Lilly USA, LLC | $104.63 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $80.48 | 2021-2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $72.43 | 2019-2023 | Tremfya |
| Dermavant Sciences, INC. | $71.09 | 2024 | Vtama |
| Organon LLC | $60.58 | 2023-2024 | Hadlima |
| Leo Pharma INC. | $56.11 | 2022-2023 | Adbry |
| Incyte Corporation | $37.92 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.04 | 2024 | Spevigo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.73 | 2025 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $9.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Olmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.